信立泰(002294.SZ)发布上半年业绩，归母净利润3.65亿元，增长6.10%

Core Viewpoint - The company reported a revenue of 2.131 billion yuan for the first half of 2025, reflecting a year-on-year growth of 4.32% and a net profit attributable to shareholders of 365 million yuan, which is a 6.10% increase compared to the previous year [1] Financial Performance - Revenue for the reporting period was 2.131 billion yuan, up 4.32% year-on-year [1] - Net profit attributable to shareholders reached 365 million yuan, marking a 6.10% increase [1] - Net profit excluding non-recurring gains and losses was 347 million yuan, showing a growth of 3.93% [1] - Basic earnings per share were 0.33 yuan [1] Product Development and Market Position - The company experienced significant growth in sales of patented and new products, which have become a core pillar of its performance [1] - In the hypertension sector, the company has established a differentiated product portfolio, continuously enriching it with products such as Xinlitai (ARB class), Xinchao Tuo (ARNI class), and Fuli Tain (ARB/CCB compound preparation) [1] - The product offerings are designed to precisely meet the medication needs of different patients [1]